|
[1]GESSONI G, MANONI F.Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area:a seroepidemiological study[J].Eur J Med, 1993, 2 (2) :79-82.
|
|
[2]GOODMAN ZD, MAKHLOUF HR, LIU L, et al.Pathology of chronic hepatitis C in children:liver biopsy findings in the PedsC Trial[J].Hepatology, 2008, 47 (3) :836-843.
|
|
[3]ZHU SS, ZENG QL, DONG Y, et al.Interferon-αplus ribavirin yields98%sustained virologic response in children aged 1-5 years with iatrogenic chronic hepatitis C[J].Hepatol Int, 2015, 9 (4) :578-585.
|
|
[4]PUOTI C, GUARISCO R, BELLIS L, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 50 (1) :322.
|
|
[5]KONG D, WU D, WANG T, et al.Detection of viral antigens in renal tissue of glomerulonephritis patients without serological evidence of hepatitis B virus and hepatitis C virus infection[J].Int J Infect Dis, 2013, 17 (7) :535-538.
|
|
[6]LIDAR M, LIPSCHITZ N, AGMON-LEVIN N, et al.Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia[J].Clin Rev Allergy Immunol, 2012, 42 (2) :238-246.
|
|
[7]CORNPROPST M, DENNING J, CLEMONS D, et al.The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977[J].J Hepatol, 2012, 56 (1) :s433-s433.
|
|
[8]KWO PY, BADSHAH MB.New hepatitis C virus therapies:drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renel disease[J].Curr Opin Organ Transplant, 2015, 20 (3) :235-241.
|
|
[9]SUDA G, FURUSYO N, TOYODA H, et al.Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection:a nationwide retrospective study in Japan[J].J Gastroenterol, 2018, 53 (1) :119-128.
|
|
[10]TANEJA S, DUSEJA A, de A, et al.Successful treatment of chronic hepatitis C infection with directly acting antivirals in renaltransplant recipients[J].Nephrology (Cariton) , 2017.[Epub ahead of print]
|
|
[11]BRIZI F, DIXIT V, MESSA P, et al.Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients:metaanalysis of clinical studies[J].J Viral Hepat, 2014, 21 (10) :681-689.
|
|
[12]CARBONE M, LENCI I, BAIOCCHI L.Prevention of hepatitis C recurrence after liver transplantation:an update[J].World J Gastrointest Pharmacol Ther, 2012, 3 (4) :36-48.
|
|
[13]AKAMATSU N, SUGAWARA Y.Liver transplantation and hepatitis C[J].Int J Hepatol, 2012, 2012:686135.
|
|
[14]PASCASIO JM, VINAIXA C, FERRER MT, et al.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation[J].J Hepatol, 67 (6) :1168-1176.
|
|
[15]ZEUZEM S, MENSA FJ.Concordance between SVR12 and SVR24in genotype 1 HCV patients receiving interferon-free treatment in the SOUND-C2 study[J].Hepatology, 2013, 58 (4) :1516.
|
|
[16]BERNUTH S, GRIMM D, VOLLMAR J, et al.Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation:a real-world cohort[J].Drug Des Devel Ther, 2017, 12 (11) :21318-21388.
|
|
[17]WILLEMSE SB, RAZAVI-SHEARER D, ZUURE FR, et al.The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms[J].Neth J Med, 2015, 73 (9) :417-431.
|
|
[18]van der MEER AJ, VELDT BJ, FELD JJ, et al.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis[J].JAMA, 2012, 308 (24) :2584-2593.
|
|
[19]ALEMAN S, RAHBIN N, WEILAND O, et al.A risk for hepatocellular carcinoma persistslong-term after sustained virologic responsein patients with hepatitis C-associated livercirrhosis[J].Clin Infect Dis, 2013, 57 (2) :230-650.
|
|
[20]ASAHINA Y, TSUCHIYA K, NISHIMURA T, et al.α-Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C[J].Hepatology, 2013, 58 (4) :1253-1262.
|
|
[21]GEORGE SL, BACON BR, BRUNT EM, et al.Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy:a 5-year follow-up of 150 patients[J].Hepatology, 2009, 49 (3) :729-738.
|
|
[22]NAGAOKI Y, AIKATA H, NAKANO N, et al.Development of hepatocellular carcinoma in patients withhepatitis C virus infection who achieved sustained virologicalresponse following interferon therapy:a large-scale, long-termcohort study[J].J Gastroenterol Hepatol, 2016, 31 (5) :1009-1015.
|
|
[23]EL-SERAG HB, KANWAL F, RICHARDSON P, et al.Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection[J].Hepatology, 2016, 64 (1) :130-137.
|
|
[24]CONTI F, BUONFIGLIOLI F, SCUTERI A, et al.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals[J].J Hepatol, 2016, 65 (4) :727-733.
|
|
[25]WIEGAND J, BUGGISCH P, BOECHER W, et al.Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection:the HEP-NET acute-HCV-II study[J].Hepatology, 2006, 43 (2) :250-256.
|
|
[26]SANTANTONIO T, FASANO M, SINISI E, et al.Efficacy of a 569 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after 570 failure of spontaneous clearance[J].J Hepatol, 2005, 42 (3) :329-333.
|
|
[27]European Association for Study of Liver.EASL Clinical Practice Guidelines:management of 445 hepatitis C virus infection[J].J Hepatol, 2014, 60 (2) :392-420.
|
|
[28]SANTANTONIO T, FASANO M, SAGNELLI E, et al.Acute hepatitis C:a 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin[J].Hepatology, 2014, 59 (6) :2101-2109.
|
|
[29]JAMALIDOUST M, NAMAYANDEH M, MOGHADAMI M, et al.Comparison of HCV viral load and its genotype distributions in HCV mono-and HIV/HCV co-infected illicit drug users[J].Virol J, 2017, 14 (1) :127.
|
|
[30]NEUKAM K, MORANO-AMADO LE, RIVERO-JUAREZ A, et al.HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals:a prospective cohort study[J].HIV Clin Trials, 2017, 18 (3) :126-134.
|
DownLoad: